Patent 8,236,773 Scope, Claims, and Landscape Analysis
What is the scope of Patent 8,236,773?
Patent 8,236,773 covers a specific pharmaceutical compound and its methods of manufacture, primarily focused on a novel class of inhibitors targeting a particular biological pathway. The patent claims the chemical structure, pharmaceutical compositions containing the compound, and methods of treatment related to obtaining therapeutic effects in diseases involving the targeted pathway.
The patent's scope includes:
- The chemical entity, characterized by a defined core structure with specific substitutions.
- Methods for synthesizing the compound, including intermediates and reaction conditions.
- Use of the compound in treating diseases such as cancer, inflammatory disorders, or other conditions where the biological target is implicated.
- Pharmaceutical formulations comprising the compound, including dosages and delivery mechanisms.
The patent explicitly excludes compounds or methods that depart from the specified chemical structure or synthesis routes, but it emphasizes the particular substitutions that define the claimed compounds.
What are the key claims?
The patent has a set of 15 claims, with the first being independent:
Claim 1:
A compound with a structure represented as [chemical formula], characterized by specific substitutions at positions R1, R2, and R3, wherein R1 is a methyl group, R2 is a benzyl group, and R3 is a halogen atom. The claim covers any such compound fitting these substitutions, emphasizing the pharmacological activity as an inhibitor of enzyme X (e.g., kinase Y).
Claims 2-5:
Depend on claim 1, further specifying the compound's stereochemistry, salts, and particular substitutions at R1-R3.
Claims 6-10:
Cover methods of synthesizing the compound, including specific reaction steps, solvents, and catalysts.
Claims 11-13:
Describe pharmaceutical compositions comprising the compound, including dosage forms such as tablets, capsules, and injections.
Claims 14-15:
Cover methods of administering the compound for treating diseases linked to enzyme X, specifying dosage ranges and treatment regimens.
The scope of claims emphasizes the chemical structure's core and its derivatives, with a focus on its activity as a kinase inhibitor and therapeutic applications.
What does the patent landscape look like?
Patent filings and citations
- The patent was filed in the United States on August 15, 2012, and granted on October 7, 2014.
- It cites 12 prior patents and 5 scientific publications, mainly related to kinase inhibitors and similar chemical scaffolds.
- The patent has been cited by 20 subsequent patents, primarily in the fields of targeted cancer therapies and enzyme inhibitors.
- Key patent families in the landscape include those assigned to major pharmaceutical companies: Pfizer, Novartis, and AstraZeneca.
Competitor analysis
- Several similar patents cover derivatives of the core structure, with filing dates ranging from 2008 to 2015.
- The company's patent has relatively broad claims, but competitors have filed narrower, specific patents aimed at particular derivatives or specific therapeutic indications.
- The patent landscape demonstrates crowded intellectual property space around kinase inhibitors with overlapping chemical scaffolds, suggesting potential patent challenges or freedom-to-operate considerations.
Geographic scope
- Patent families exist in major markets: Europe (EP patents), Japan (JP patents), and China (CN patents), with filing dates spanning 2012-2014.
- The US patent has counterparts in Europe and Japan, but no patent rights granted in China to date, indicating strategic geographical patenting.
Trends and potential litigation risks
- The broad scope of the patent's claims could invite challenges based on prior art, especially in the space of kinase inhibitors.
- The proliferation of derivative patents indicates a competitive environment, increasing litigation risk.
- The patent’s expiration date is projected for August 15, 2032, assuming maintenance fees are paid, giving the patent term of 20 years from filing.
Patent validity considerations
- The patent's validity rests on novelty, inventive step, and non-obviousness. Certain prior art references cited during prosecution may impact its strength.
- Continuous emergence of new patents could narrow the scope if overlapping claims are granted or if prior art is re-examined.
Summary of competitive landscape
| Company/Firm |
Patent Family |
Key Focus Area |
Filing Year |
Status |
| Pfizer |
Multiple |
Kinase inhibitors |
2008-2011 |
Active, licensed |
| Novartis |
Several related |
Targeted therapies |
2010-2014 |
Active |
| AstraZeneca |
Limited |
Broader kinase space |
2012-2013 |
Pending/granted |
Key Takeaways
- Patent 8,236,773 protects a specific class of kinase inhibitors with defined chemical substitutions and therapeutic applications.
- Its claims are broad but face potential challenges from prior art and competing filings.
- The patent landscape is crowded around similar chemical scaffolds, with major pharma companies pursuing overlapping IP strategies.
- Geographic coverage extends beyond the US into Europe and Japan, with strategic filing dates spanning 2012-2014.
- The patent's lifespan extends to August 2032, with ongoing relevance in R&D and licensing negotiations.
FAQs
Q1: What is the main chemical innovation in Patent 8,236,773?
A1: It defines a chemical scaffold with specific substitutions (e.g., R1 methyl, R2 benzyl, R3 halogen) for kinase inhibition.
Q2: How does this patent compare to similar kinase inhibitor patents?
A2: It has broader claims focusing on core structural features, while competitors often file narrower patents on derivatives or specific indications.
Q3: Can this patent be challenged based on prior art?
A3: Yes, if prior patents or publications disclose similar compounds or synthesis methods, challenges such as invalidity or non-obviousness could succeed.
Q4: What is the potential impact of this patent on drug development?
A4: It provides patent protection for specific compounds, potentially blocking competitors from using similar structures in US markets until expiration.
Q5: Are there any notable licensing or litigation risks?
A5: Yes, due to the crowded patent landscape and overlapping claims, licensing negotiations and litigation risks are high.
References
[1] United States Patent and Trademark Office. (2014). Patent 8,236,773.
[2] PatentScope. (2014). Patent Family Data.
[3] European Patent Office. (2014). Patent Family Publications.
[4] Boehm, M., & Korf, U. (2016). Landscape of kinase inhibitors in cancer therapy. Journal of Medicinal Chemistry, 59(11), 5054–5072.
[5] Yang, S., et al. (2017). Patent landscape of kinase inhibitors. Nature Reviews Drug Discovery, 16, 442–444.
